Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 615-626

  Tran, Jonathan Q ^a,c   Petersen, Carolyn ^a   Garrett, May ^a   Hee, Brian ^a   Kerr, Bradley M ^a,b  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; DELAVIRDINE; EFAVIRENZ; KETOCONAZOLE; NELFINAVIR; NEVIRAPINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CARBAMATES; DELAVIRDINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REFERENCE VALUES; SULFONAMIDES;

EID: 0036917788     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.128868     Document Type: Article

References (51)

1. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.
2. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Safety 1999;20:147-69.
3. Burger DM, Hoetelmans RM, Koopmans PP, Meehorst PL, Mulder JW, Hekster YA, et al. Clinically relevant drug interactions with antiretroviral agents. Antivir Ther 1997;2:149-65.
4. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001;40:893-905.
5. van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PI, Longe JMA, Beijnen JH, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience. Antivir Ther 2001;6:201-29.
6. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J Pharmacol Exp Ther 1996;277:423-31.
7. Chiba M, Hensleigh M, Lin JH. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 1997;53:1187-95.
8. Eagling VA, Wiltshire H, Whitcombe IWA, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 2002;32: 1-17.
9. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7.
10. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, et al. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 1998;26:609-16.
11. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999;27: 902-8.
12. Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne A, Ackland MJ, et al. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998;26:631-9.
13. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999;27:1488-95.
14. Adkins JC, Noble S. Efavorenz. Drugs 1998;56:1055-64.
15. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochrome P450: High risk associated with ritonavir. J Clin Pharmacol 1998;38:106-11.
16. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-4.
17. von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole. Eur J Clin Pharmacol 2000;56:259-61.
18. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-6.
19. Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, Polli JW. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001;29:754-60.
20. Hsu A, Granneman GR, Witt F, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997;41:898-905.
21. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavorenz. Br J Clin Pharmacol 2001;51:213-7.
22. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999;27:895-901.
23. Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J Acquir Immun Defic Syndr Hum Retrovirol 1998;18:252-9.
24. Tran JQ, Gerber JG, Kerr BM. Delavirdine. Clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001;40:207-26.
25. Agenerase Package Insert. Research Triangle Park (NC): GlaxoSmithKline; 2002.
26. Polk RE, Crouch MA, Israel DS, Pastor A, Sadler BM, Chittick GE, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378-84.
27. Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, et al. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother 2001;45:3663-8.
28. Duval X, Le Moing V, Longuet C, Leport C, Vilde JL, Lamotte C, et al. Efavorenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir. Antimicrob Agents Chemother 2000;44:2593.
29. Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, et al. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45:502-8.
30. Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 2001;15:1009-18.
31. Rescriptor Package Insert. San Diego: Agouron Pharmaceuticals; 1999.
32. Cox S, Conway B, Freimuth W, Berber E, Paxton L, Carel B, et al. Pilot study of BID and TID combinations of saquinavir-SGC (S), delavirdine (D), zidovudine (ZDV) and lamivudine (3TC) as initial therapy: Pharmacokinetic (PK) interaction between S-SGC and D [abstract 82]. In: Proceedings of the Seventh Conference on Retroviruses and Opportunistic Infections; 2000 January 30-February 4; San Francisco, Calif. San Francisco: The Conference; 2000.
33. Tran JQ, Cox SJ, Kerr BM, Lillibridge J, Wathen L, Greenwald C, et al. Pharmacokinetics (PK) of indinavir (IDV) at A reduced daily dose and dosing frequency in the presence of delavirdine (DLV) in HIV-infected patients. In: Proceedings of the First International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 July 8-11; Buenos Aires, Argentina. Buenos Aires: The Conference; 2001.
34. Voorman RL, Maio SM, Payne A, Zhao Z, Koeplinger KA, Wang X. Microsomal metabolism of delavirdine: Evidence for mechanism based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998;287:381-8.
35. Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, et al. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin Pharmacol Ther 1997;61:531-43.
36. Morse GD, Shelton MJ, Hewitt RG, Adams JM, Baldwin JR, Della Coletta AA, et al. Ritonavir pharmacokinetics during combination therapy with delavirdine [abstract 343]. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, Illinois. Chicago: The Conference; 1998.
37. Cox SR, Schneck DW, Herman SD, Carel BD, Gullotti BR, Kerr BM, et al. Delavirdine and nelfinavir: A pharmacokinetic drug-drug interaction study in healthy adult volunteers [abstract 345]. In: Proceedings of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, Illinois. Chicago: The Conference; 1998.
38. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 1999;43:1686-92.
39. Staton BA, Johnson MG, Friis JM, Adams WJ. Simple, rapid, and sensitive high-performance liquid chromatographic determination of delavirdine and its N-desisopropyl metabolite in human plasma. J Chromatogr B Biomed Appl 1995;668:99-106.
40. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, et al. Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001;23:553-5.
41. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73.
42. Gerber JG, Rhodes JG. Cytochrome P450 2B6 (CYP2B6) metabolizes methadone (M) preferentially and stereospecifically. An explanation of drug interaction with antiretroviral drugs [abstract 2.2]. In: Proceedings of the First International Workshop on Clinical Pharmacology of HIV Therapy; 2000 March 30-31; Noordwijk, The Netherlands. Noordwijk: The Workshop; 2000.
43. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: Results of AIDS clinical trials group (ACTG) 401. J Acquir Immun Defic Syndr 2001;27:153-60.
44. Begre S, von Bardeleben U, Ladewig D, Jaquet-Rochat S, Cosendai-Savary L, Golay KP, et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002;22:211-5.
45. Mauss S, Schmutz G, Kuschak D. Unfavorable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 2002;16:296-7.
46. Khanlou H, Grahma E, Brill M, Farthing C. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002;46:797-812.
47. Bertz R, Foit C, Burt D, Hsu A, Chiu YL, Chira T, et al. Assessment of the multiple dose pharmacokinetic interaction between Kaletra (lopinavir/ritonavir) and amprenavir in healthy volunteers [abstract 7.6]. In: Proceedings of the Third International Workshop on Clinical Pharmacology of HIV Therapy; 2002 Apr 11-13; Washington, DC. Washington: The Workshop; 2002.
48. Sadler BM, Gillotin C, Lou Y, Stein DS. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob Agents Chemother 2001;45:30-37.
49. 1-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001;45:852-56.
50. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 2000;14:1333-9.
51. Anderson PL, Fletcher CV. Clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr Infect Dis Rep 2001;3:381-7.